COVID-19 Treatments

Companies working on COVID-19 Vaccines, Treatments and Testing

Vaccines

CompanyMarket Cap
Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million
BioNTech (NASDAQ:BNTX) $12.2 billion
CSL Behring (OTC:CSLLY) $89.8 billion
Dynavax (NASDAQ:DVAX) $293.9 million
GlaxoSmithKline (NYSE:GSK)$93.7 billion
Inovio Pharmaceuticals (NASDAQ:INO) $1.2 billion
Johnson & Johnson (NYSE:JNJ) $357.9 billion
Moderna (NASDAQ:MRNA) $11.4 billion
Novavax (NASDAQ:NVAX)$821.8 million
Pfizer (NYSE:PFE) $190.2 billion
Sanofi (NASDAQ:SNY) $112.9 billion
TranslateBio (NASDAQ:TBIO) $614.1 million

Treatments

Company
Market Cap
AbbVie (NYSE:ABBV)
$113.7 billion
Adaptive Biotechnologies (NASDAQ:ADPT) 
$3.4 billion
Alexion Pharmaceuticals (NASDAQ:ALXN)
$21.7 billion
Alnylam Pharmaceuticals (NASDAQ:ALNY)
$12.6 billion
Amgen (NASDAQ:AMGN)
$122.9 billion
Bayer (OTC:BAYRY)
$60.2 billion
Biogen (NASDAQ:BIIB)
$54.1 billion
CSL Behring
$89.8 billion
CytoDyn (NASDAQOTH:CYDY)
$1.3 billion
Emergent BioSolutions (NYSE:EBS) 
$3.1 billion
Gilead Sciences (NASDAQ:GILD)
$96.6 billion
Grifols (NASDAQ:GRFS)
$19.5 billion
Incyte (NASDAQ:INCY)
$18 billion
Eli Lilly (NYSE:LLY)
$135.8 billion
Mesoblast (NASDAQ:MESO)
$6.1 billion
Novartis (NYSE:NVS)
$193.1 billion
Regeneron Pharmaceuticals (NASDAQ:REGN)
$55.5 billion
Roche Holding (OTC:RHHBY)
$286.7 billion
Sanofi
$112.9 billion
Takeda Pharmaceutical (NYSE:TAK)
$47.6 billion
Vanda Pharmaceuticals (NASDAQ:VNDA)
$568.7 million
Vir Biotechnology (NASDAQ:VIR)
$3.9 billion

Testing

Company Market Cap
Abbott Labs (NYSE:ABT)$142 billion
Bayer$60.2 billion
Becton Dickinson (NYSE:BDX)$63.2 billion
bioMerieux (OTC:BMXMF)$13.2 billion
Co-Diagnostics (NASDAQ:CODX)$273 million
Danaher (NYSE:DHR)$98.5 billion
Eli Lilly$135.8 billion
Grifols$19.5 billion
LabCorp (NYSE:LH)
$11.9 billion
OPKO Health (NASDAQ:OPK)$817.2 million
Quest Diagnostics (NYSE:DGX)$10.4 billion
Roche Holdings$286.7 billion
Thermo Fisher Scientific (NYSE:TMO)$117.7 billion

Datasource:- The Montley Fool

Global Coronavirus COVID-19 Clinical Trials

1133

Trials Selected

Dashboard of Clinical Trials for COVID-19

In response to the global coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of clinical candidate interventions to treat COVID-19 are emerging at an unprecedented rate. As of April 21, 2020, well over 500 clinical trials have been registered at the various international and national clinical trial registry sites. Findings from randomised clinical trials that have been published as of April 21, 2020, have investigated the efficacy of lopinavir–ritonavir compared with standard of care, hydroxychloroquine compared with best supportive care, favipiravir compared with arbidol, and lopinavir–ritonavir compared with arbidol. Other non-randomised trials have investigated hydroxychloroquine versus hydroxychloroquine combined with azithromycin. Over 300 trials are enrolling participants and cover further investigations of the above drugs and promising therapies such as remdesivir, IL-6 inhibitors (tocilizumab and sarilumab), convalescent plasma therapy, stem-cell transfusion, vaccine candidates, several other well known direct acting antivirals, and traditional Chinese medicines. Most of these trials will offer comparative efficacy data versus standard of care according to local COVID-19 treatment guidelines, but a handful of randomised controlled trials will also provide head-to-head evidence between high profile interventions. The figure shows the network of completed, ongoing, and planned COVID-19 interventional clinical trials of these interventions or intervention groups that are being explored in at least two trials.

Figure: Evidence network of COVID-19 clinical trials of top 15 interventions Circles (node) represent interventions or intervention groups (categories). Lines between two circles indicate comparisons in clinical trials. The numbers on the lines are the number of clinical trials making the specific comparison. Circular arrows and numbers indicate the number of non-comparative clinical trials in which that intervention is included. A few trials examining combination therapies are excluded from the figure due to space limitations. COVID-19=coronavirus disease 2019. LPV/r (lopinivir–ritonavir). *Includes trials on hydroxychloroquine and chloroquine. (Datasource: The Lancet)

Contact Us